CANCER–INDUCED DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS
https://doi.org/10.21294/1814-4861-2021-20-4-146-151
Abstract
the purpose of the study was to analyze facts and mechanisms of the development of second malignancies after radiodiagnostic and radiotherapy procedures as well as after different medicamental treatments. the search for relevant articles published over the last 6 years was carried out using medline, elibrary, pubmed databases, and 34 publications were included in this review. the risk of second malignancies from ct scans and radiation therapy is increased by 1.5–3 times in cancer patients. some drugs for treatment of chronic non-oncology diseases and many chemotherapeutic agents possess high carcinogenic potential in longtime period. invasive diagnostic and treatment methods, especially organ transplantations, have protumorogenic effects. some of the diagnostic and treatment methods used in oncology should be considered as «inevitable oncoiatrogenic». applications of these methods require reasonable limitations.
About the Authors
A. V. ShaposhnikovRussian Federation
MD, DSc, Professor, Leading Researcher, Department of General Oncology
Author ID (Scopus) 7005752070
63, 14 line street, 344037, Rostov-on-don, Russia
O. I. Kit
Russian Federation
MD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, General Director
Researcher ID (WOS): U-2241-2017. Author ID (Scopus): 55994103100
63, 14 line street, 344037, Rostov-on-don, Russia
E. A. Dzhenkova
Russian Federation
DSc, Associate Professor
Author ID (Scopus): 6507889745. Researcher ID (WOS): K-9622-2014
63, 14 line street, 344037, Rostov-on-don, Russia
K. V. Legostaeva
Russian Federation
student
29, Nakhchivansky lane, 344037, Rostov-on-don, Russia
References
1. Madia F., Worth A., Whelan M., Corvi R. Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment. Environ Int. 2019 Jul; 128: 417–429. doi: 10.1016/j.envint.2019.04.067.
2. What are the Radiation Risks from CT? [Internet]. URL: https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/whatare-radiation-risks-ct (cited 22.05.2020).
3. Hong J.Y., Han K., Jung J.H., Kim J.S. Association of Exposure to Diagnostic Low-Dose Ionizing Radiation With Risk of Cancer Among Youths in South Korea. JAMA Netw Open. 2019 Sep 4; 2(9): e1910584. doi: 10.1001/jamanetworkopen.2019.10584.
4. Shao Y.H., Tsai K., Kim S., Wu Y.J., Demissie K. Exposure to Tomographic Scans and Cancer Risks. JNCI Cancer Spectr. 2019 Nov 14; 4(1): pkz072. doi: 10.1093/jncics/pkz072.
5. Zelensky A.N., Schoonakker M., Brandsma I., Tijsterman M., van Gent D.C., Essers J., Kanaar R. Low dose ionizing radiation strongly stimulates insertional mutagenesis in a γH2AX dependent manner. PLoS Genet. 2020 Jan 16; 16(1): e1008550. doi: 10.1371/journal.pgen.1008550.
6. Fernandez-Antoran D., Piedrafita G., Murai K., Ong S.H., Herms A., Frezza C., Jones P.H. Outcompeting p53-Mutant Cells in the Normal Esophagus by Redox Manipulation. Cell Stem Cell. 2019 Sep 5; 25(3): 329–341.e6. doi: 10.1016/j.stem.2019.06.011.
7. Schultz C.H., Fairley R., Murphy L.S., Doss M. The Risk of Cancer from CT Scans and Other Sources of Low-Dose Radiation: A Critical Appraisal of Methodologic Quality. Prehosp Disaster Med. 2020 Feb; 35(1): 3–16. doi: 10.1017/S1049023X1900520X.
8. Rombouts A.J.M., Hugen N., Elferink M.A.G., Poortmans P.M.P., Nagtegaal I.D., de Wilt J.H.W. Increased risk for second primary rectal cancer after pelvic radiation therapy. Eur J Cancer. 2020 Jan; 124: 142–151. doi: 10.1016/j.ejca.2019.10.022.
9. Charas T., Taggar A., Zelefsky M.J. Second malignancy risk in prostate cancer and radiotherapy. Future Oncol. 2017 Feb; 13(5): 385–389. doi: 10.2217/fon-2016-0503.
10. Dracham C.B., Shankar A., Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018 Jun; 36(2): 85–94. doi: 10.3857/roj.2018.00290.
11. Pottegård A., Pedersen S.A., Schmidt S.A.J., Hölmich L.R., Friis S., Gaist D. Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma. JAMA Intern Med. 2018 Aug 1; 178(8): 1120–1122. doi: 10.1001/jamainternmed.2018.1652.
12. Cheung K.S., Chan E.W., Wong A.Y.S., Chen L., Wong I.C.K., Leung W.K. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018 Jan; 67(1): 28–35. doi: 10.1136/gutjnl-2017-314605.
13. Brusselaers N., Sadr-Azodi O., Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020 Apr; 55(4): 453–461. doi: 10.1007/s00535-019-01652-z.
14. Byrd J.B., Chertow G.M., Bhalla V. Hypertension Hot Potato –Anatomy of the Angiotensin-Receptor Blocker Recalls. N Engl J Med. 2019 Apr 25; 380(17): 1589–1591. doi: 10.1056/NEJMp1901657.
15. Manolis A.S. Carcinogenic Impurities in Generic Sartans: An Issue of Authorities Control or a Problem with Generics? Rhythmos. 2019; 14(2): 23–6.
16. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market [Internet]. URL: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantacmarket (cited 22.05.2020).
17. Levitan D. FDA Warns of Bladder Cancer Risk From Diabetes Drug. [Internet]. URL: https://www.cancernetwork.com/view/fda-warnsbladder-cancer-risk-diabetes-drug (cited 22.05.2020).
18. Morch L.S., Scovlund C.W., Hannaford P.C., Iversen L., Fielding S., Lidegaard O. Contemporary Hormonal Conception and the Risk of Breast Cancer. N Engl J Med. 2017; 377: 2228–2239. doi: 10.1056/NEJMoa170032.
19. Collaboration Group on Hormonal Factors in Brest Cancer. Type and timing of menopausal hormone Therapy and breast cancer risk. Lancet. 2019; 394: 1150–1168.doi: 10.1016/SO140-6736 (19) 31709-X.
20. Solenova L.G. Second primary malignancies in cancer survivors: epidemiology, role of anticancer therapy. Advances in Molecular Oncology, 2016; 3: 30–43. (in Russian). doi: 10-17650/2313-805x-2016-3-3-30-43.
21. Morton L.M., Dores G.M., Schonfeld S.J., Linet M.S., Sigel B.S., Lam C.J.K., Tucker M.A., Curtis R.E. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. JAMA Oncol. 2019 Mar 1; 5(3): 318–325. doi: 10.1001/jamaoncol.2018.5625.
22. Belitskiy G.A., Lesovaya E.A., Kirsanov K.I., Yakubovskaya M.G. Second primary malignancies of cancer patients: treatment-related carcinogenesis. Advances in Molecular Oncology. 2016; 3: 44–55. (in Russian). doi: 10.17650/2313-805X-2016-3-3-44-55.
23. Schaapveld M., Aleman B.M., van Eggermond A.M., Janus C.P., Krol A.D., van der Maazen R.W., Roesink J., Raemaekers J.M., de Boer J.P., Zijlstra J.M., van Imhoff G.W., Petersen E.J., Poortmans P.M., Beijert M., Lybeert M.L., Mulder I., Visser O., Louwman M.W., Krul I.M., Lugtenburg P.J., van Leeuwen F.E. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med. 2015; 373(26): 2499–511. doi: 10.1056/NEJMoa1505949.
24. Turcotte L.M., Liu Q., Yasui Y., Henderson T.O., Gibson T.M., Leisenring W., Arnold M.A., Howell R.M., Green D.M., Armstrong G.T., Robison L.L., Neglia J.P. Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2019 Dec 1; 37(34): 3310–19. doi: 10.1200/JCO.19.00129.
25. Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer. 2019 Dec; 19(12): 667–685. doi: 10.1038/s41568-019-0209-6.
26. WHO. Clobal Surveillance and Monitoring System for Substandart and Falsified Medical Products. 2017. 73 p.
27. Karagiannis G.S., Condeelis J.S., Oktay M.H. ChemotherapyInduced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions. Cancer Res. 2019 Sep; 79(18): 4567–76. doi: 10.1158/0008-5472.CAN-19-1147.
28. Backes Y., Seerden T.C.J., van Gestel R.S.F.E., Kranenburg O., Ubink I., Schiffelers R.M., van Straten D., van der Capellen M.S., van de Weerd S., de Leng W.W.J., Siersema P.D., Offerhaus G.J.A., Morsink F.H., Ramphal W., Terhaar Sive Droste J., van Lent A.U.G., Geesing J.M.J., Vleggaar F.P., Elias S.G., Lacle M.M., Moons L.M.G. Tumor Seeding During Colonoscopy as a Possible Cause for Metachronous Colorectal Cancer. Gastroenterology. 2019 Nov; 157(5): 1222–1232.e4. doi: 10.1053/j.gastro.2019.07.062.
29. Shyamala K., Girish H.C., Murgod S. Risk of tumor cell seeding through biopsy and aspiration cytology. J Int Soc Prev Community Dent. 2014 Jan; 4(1): 5–11. doi: 10.4103/2231-0762.129446.
30. Alieva M., van Rheenen J., Broekman M.L.D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin Exp Metastasis. 2018 Apr; 35(4): 319–331. doi: 10.1007/s10585-018-9896-8.
31. Mahale P., Engels E.A., Lynch C.F., Morton L.M. Cancer risk following post-transplant lymphoproliferative disorders in solid organ transplant recipients. Br J Haematol. 2019 Jul; 186(2): 347–351. doi: 10.1111/bjh.15828.
32. Park B., Yoon J., Choi D., Kim H.J., Jung Y.K., Kwon O.J., Lee K.G. De novo cancer incidence after kidney and liver transplantation: Results from a nationwide population based data. Sci Rep. 2019 Nov 20; 9(1): 17202. doi: 10.1038/s41598-019-53163-9.
33. Goubran H.A., Elemary M., Radosevich M., Seghatchian J., El-Ekiaby M., Burnouf T. Impact of Transfusion on Cancer Growth and Outcome. Cancer Growth Metastasis. 2016 Mar 13; 9: 1–8. doi: 10.4137/CGM.S32797.
34. Cupit-Link M.C., Kirkland J.L., Ness K.K., Armstrong G.T., Tchkonia T., LeBrasseur N.K., Armenian S.H., Ruddy K.J., Hashmi S.K. Biology of premature ageing in survivors of cancer. ESMO Open. 2017 Dec 18; 2(5): e000250. doi: 10.1136/esmoopen-2017-000250.
Review
For citations:
Shaposhnikov A.V., Kit O.I., Dzhenkova E.A., Legostaeva K.V. CANCER–INDUCED DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS. Siberian journal of oncology. 2021;20(4):146-151. (In Russ.) https://doi.org/10.21294/1814-4861-2021-20-4-146-151